The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.

Autor: Weber CJ; Alzheimer's Association Chicago Illinois USA., Carrillo MC; Alzheimer's Association Chicago Illinois USA., Jagust W; School of Public Health and Helen Wills Neuroscience Institute University of California Berkeley Berkeley California USA., Jack CR Jr; Department of Radiology Mayo Clinic Rochester Minnesota USA., Shaw LM; Department of Pathology and Laboratory Medicine Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA., Trojanowski JQ; Department of Pathology and Laboratory Medicine Perelman School of Medicine Institute on Aging Perelman School of Medicine Alzheimer's Disease Core Center, Perelman School of Medicine Udall Parkinson's Research Center Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA., Saykin AJ; Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center Department of Medical and Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA., Beckett LA; Division of Biostatistics Department of Public Health Sciences University of California Davis California USA., Sur C; Merck Research Laboratories Merck Kenilworth New Jersey USA., Rao NP; Department of Psychiatry National Institute of Mental Health and Neurosciences Bengaluru Karnataka India., Mendez PC; Centro de Memoria FLENI Montañeses, 2325 (C1428AQK), Bs As Buenos Aires Argentina., Black SE; Department of Medicine (Neurology) Hurvitz Brain Sciences Program Canadian Partnership for Stroke Recovery, and LC Campbell Cognitive Neurology Research Unit Hurvitz Brain Sciences Research Program Sunnybrook Research Institute Sunnybrook Health Sciences Centre University of Toronto Toronto Canada., Li K; Department of Radiology Xuanwu Hospital of Capital Medical University Beijing China., Iwatsubo T; Department of Neuropathology Graduate School of Medicine The University of Tokyo Tokyo Japan., Chang CC; Department of General Neurology and Institute for Translational Research in Biomedicine Kaohsiung Chang Gung Memorial Hospital Chang Gung University College of Medicine Kaohsiung Taiwan., Sosa AL; National Institute of Neurology and Neurosurgery of Mexico Mexico City Mexico., Rowe CC; Department of Molecular Imaging and Therapy Austin Health and Florey Department of Neuroscience and Mental Health University of Melbourne Melbourne Victoria Australia., Perrin RJ; Charles F. and Joanne Knight Alzheimer Disease Research Center Department of Pathology and Immunology Department of Neurology Washington University School of Medicine Saint Louis Missouri USA., Morris JC; Charles F. and Joanne Knight Alzheimer Disease Research Center Department of Neurology Washington University School of Medicine Saint Louis Missouri USA., Healan AMB; Independent Science Writer and Editor Nashville Tennessee USA., Hall SE; Alzheimer's Association Chicago Illinois USA., Weiner MW; Department of Veterans Affairs Medical Center Center for Imaging of Neurodegenerative Diseases Department of Radiology Department of Medicine Department of Psychiatry Department of Neurology University of California San Francisco California USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2021 Dec 31; Vol. 7 (1), pp. e12226. Date of Electronic Publication: 2021 Dec 31 (Print Publication: 2021).
DOI: 10.1002/trc2.12226
Abstrakt: The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.
Competing Interests: WJ has served as a consultant to Bioclinica, Biogen, CuraSen, Grifols, and Roche/Genentech. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. AJS and the Indiana University ADRC receives in‐kind PET precursor support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly. CS is a full‐time employee of Merck and Co., Inc. and owns shares in the company. CCR has received institutional research grants from Cerveau Technologies, Biogen, Eisai, Abbvie, Roche, and Janssen, and is also participating in Scientific Advisory Boards for Cerveau Technologies and Biogen Australia. LMS is supported by the NIA ADNI‐3 grant for which he provides QC oversight for CSF analyses using the Roche Elecsys automated platform and reagents, and has also received IIS grant support for AD biomarker studies from Roche.
(© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: